Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine
OBJECTIVE Hyperactivity of the HPA axis is a possible mechanism underlying abdominal obesity. We aimed to evaluate in premenopausal women with abdominal obesity, (i) the hypothalamic‐pituitary‐adrenal (HPA) axis responses to direct pituitary stimulation with corticotrophin releasing hormone (CRH) an...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 1997-04, Vol.46 (4), p.461-466 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 466 |
|---|---|
| container_issue | 4 |
| container_start_page | 461 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 46 |
| creator | Boushaki, F. Z. Rasio, E. Serri, O. |
| description | OBJECTIVE Hyperactivity of the HPA axis is a possible mechanism underlying abdominal obesity. We aimed to evaluate in premenopausal women with abdominal obesity, (i) the hypothalamic‐pituitary‐adrenal (HPA) axis responses to direct pituitary stimulation with corticotrophin releasing hormone (CRH) and to opioid blockade with naloxone, and (ii) the interaction between short‐term serotoninergic activation with dexfenfluramine (dF), a serotonin‐release agonist, and these responses.
DESIGN AND SUBJECTS Eight obese women (mean BMI, 35 kg/m2) with waist to hip ratio (WHR) > 0.85 were tested with CRH (1 μg/kg i.v.) and naloxone (125 μg/kg i.v.) before and at the end of two treatment periods with dF (15 mg twice daily for 7 days) and placebo (washout 7 days) in a cross‐over design. Eight normal weight control women were tested with CRH and naloxone.
RESULTS Prior to treatment, ACTH and cortisol responses to naloxone (areas under the curve) were significantly higher in obese women then in control women (P=0.027 and P=0.035 respectively). dF treatment resulted in significant (P |
| doi_str_mv | 10.1046/j.1365-2265.1997.1620975.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79069612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79069612</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4362-bf5c484dc9074f586e7addedf2b489b547a4278f3d9cf84a66783809061989f33</originalsourceid><addsrcrecordid>eNqVkF1rFDEUhoModW39CcIg4t1Mk8l3LwTZ1rZQKpRaL0MmH5h1PtZkBmf_vRl22HuvQnKe856TB4CPCFYIEna5qxBmtKxrRiskJa8Qq6HktJpfgc2p9BpsIIawhIyRt-BdSjsIIRWQn4EziSRjUG7A891hP4y_dKu7YMp9GKcw6ngotY2u122h55CK0Be6sUMXlpehcSmMh6vCee_MmIrBF9bN3vW-nWKO6d0FeON1m9z79TwHP77dPG_vyofvt_fbrw-lIZjVZeOpIYJYIyEnngrmuLbWWV83RMiGEq5JzYXHVhoviGaMCyyghAxJIT3G5-DzMXcfhz-TS6PqQjKubXXvhikpnlHJUJ3BqyNo4pBSdF7tY-jyPxWCalGqdmrxphZvalGqVqVqzs0f1ilT0zl7al0d5vqnta6T0a2PujchnbA6b00gzdiXI_Y3tO7wHwuo7c1jvuSA8hgQ0ujmU4COvxXjOJM_H2-VfKIv1-Jaqhf8D1TRodc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79069612</pqid></control><display><type>article</type><title>Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Boushaki, F. Z. ; Rasio, E. ; Serri, O.</creator><creatorcontrib>Boushaki, F. Z. ; Rasio, E. ; Serri, O.</creatorcontrib><description>OBJECTIVE Hyperactivity of the HPA axis is a possible mechanism underlying abdominal obesity. We aimed to evaluate in premenopausal women with abdominal obesity, (i) the hypothalamic‐pituitary‐adrenal (HPA) axis responses to direct pituitary stimulation with corticotrophin releasing hormone (CRH) and to opioid blockade with naloxone, and (ii) the interaction between short‐term serotoninergic activation with dexfenfluramine (dF), a serotonin‐release agonist, and these responses.
DESIGN AND SUBJECTS Eight obese women (mean BMI, 35 kg/m2) with waist to hip ratio (WHR) > 0.85 were tested with CRH (1 μg/kg i.v.) and naloxone (125 μg/kg i.v.) before and at the end of two treatment periods with dF (15 mg twice daily for 7 days) and placebo (washout 7 days) in a cross‐over design. Eight normal weight control women were tested with CRH and naloxone.
RESULTS Prior to treatment, ACTH and cortisol responses to naloxone (areas under the curve) were significantly higher in obese women then in control women (P=0.027 and P=0.035 respectively). dF treatment resulted in significant (P<0.05) reduction of ACTH and cortisol increments. In contrast, ACTH and cortisol responses to CRH were not significantly different in obese and control subjects and were unaffected by dF treatment.
CONCLUSION We conclude that women with abdominal obesity have hyperreactivity of the HPA axis to opiod blockage and that dexfenfluramine treatment reduces this hyperreactivity.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1046/j.1365-2265.1997.1620975.x</identifier><identifier>PMID: 9196609</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford BSL: Blackwell Science Ltd</publisher><subject>Adrenocorticotropic Hormone - blood ; Adult ; Biological and medical sciences ; Body Constitution ; Body Mass Index ; Corticotropin-Releasing Hormone ; Cross-Over Studies ; Female ; Fenfluramine - therapeutic use ; Humans ; Hydrocortisone - blood ; Hypothalamo-Hypophyseal System - drug effects ; Hypothalamo-Hypophyseal System - physiopathology ; Medical sciences ; Metabolic diseases ; Naloxone ; Narcotic Antagonists ; Obesity ; Obesity - blood ; Obesity - drug therapy ; Obesity - physiopathology ; Pituitary-Adrenal System - drug effects ; Pituitary-Adrenal System - physiopathology ; Serotonin Agents - therapeutic use</subject><ispartof>Clinical endocrinology (Oxford), 1997-04, Vol.46 (4), p.461-466</ispartof><rights>Blackwell Science Ltd, Oxford</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4362-bf5c484dc9074f586e7addedf2b489b547a4278f3d9cf84a66783809061989f33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2265.1997.1620975.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2265.1997.1620975.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2678405$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9196609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boushaki, F. Z.</creatorcontrib><creatorcontrib>Rasio, E.</creatorcontrib><creatorcontrib>Serri, O.</creatorcontrib><title>Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clinical Endocrinology</addtitle><description>OBJECTIVE Hyperactivity of the HPA axis is a possible mechanism underlying abdominal obesity. We aimed to evaluate in premenopausal women with abdominal obesity, (i) the hypothalamic‐pituitary‐adrenal (HPA) axis responses to direct pituitary stimulation with corticotrophin releasing hormone (CRH) and to opioid blockade with naloxone, and (ii) the interaction between short‐term serotoninergic activation with dexfenfluramine (dF), a serotonin‐release agonist, and these responses.
DESIGN AND SUBJECTS Eight obese women (mean BMI, 35 kg/m2) with waist to hip ratio (WHR) > 0.85 were tested with CRH (1 μg/kg i.v.) and naloxone (125 μg/kg i.v.) before and at the end of two treatment periods with dF (15 mg twice daily for 7 days) and placebo (washout 7 days) in a cross‐over design. Eight normal weight control women were tested with CRH and naloxone.
RESULTS Prior to treatment, ACTH and cortisol responses to naloxone (areas under the curve) were significantly higher in obese women then in control women (P=0.027 and P=0.035 respectively). dF treatment resulted in significant (P<0.05) reduction of ACTH and cortisol increments. In contrast, ACTH and cortisol responses to CRH were not significantly different in obese and control subjects and were unaffected by dF treatment.
CONCLUSION We conclude that women with abdominal obesity have hyperreactivity of the HPA axis to opiod blockage and that dexfenfluramine treatment reduces this hyperreactivity.</description><subject>Adrenocorticotropic Hormone - blood</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Body Constitution</subject><subject>Body Mass Index</subject><subject>Corticotropin-Releasing Hormone</subject><subject>Cross-Over Studies</subject><subject>Female</subject><subject>Fenfluramine - therapeutic use</subject><subject>Humans</subject><subject>Hydrocortisone - blood</subject><subject>Hypothalamo-Hypophyseal System - drug effects</subject><subject>Hypothalamo-Hypophyseal System - physiopathology</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Naloxone</subject><subject>Narcotic Antagonists</subject><subject>Obesity</subject><subject>Obesity - blood</subject><subject>Obesity - drug therapy</subject><subject>Obesity - physiopathology</subject><subject>Pituitary-Adrenal System - drug effects</subject><subject>Pituitary-Adrenal System - physiopathology</subject><subject>Serotonin Agents - therapeutic use</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1rFDEUhoModW39CcIg4t1Mk8l3LwTZ1rZQKpRaL0MmH5h1PtZkBmf_vRl22HuvQnKe856TB4CPCFYIEna5qxBmtKxrRiskJa8Qq6HktJpfgc2p9BpsIIawhIyRt-BdSjsIIRWQn4EziSRjUG7A891hP4y_dKu7YMp9GKcw6ngotY2u122h55CK0Be6sUMXlpehcSmMh6vCee_MmIrBF9bN3vW-nWKO6d0FeON1m9z79TwHP77dPG_vyofvt_fbrw-lIZjVZeOpIYJYIyEnngrmuLbWWV83RMiGEq5JzYXHVhoviGaMCyyghAxJIT3G5-DzMXcfhz-TS6PqQjKubXXvhikpnlHJUJ3BqyNo4pBSdF7tY-jyPxWCalGqdmrxphZvalGqVqVqzs0f1ilT0zl7al0d5vqnta6T0a2PujchnbA6b00gzdiXI_Y3tO7wHwuo7c1jvuSA8hgQ0ujmU4COvxXjOJM_H2-VfKIv1-Jaqhf8D1TRodc</recordid><startdate>199704</startdate><enddate>199704</enddate><creator>Boushaki, F. Z.</creator><creator>Rasio, E.</creator><creator>Serri, O.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199704</creationdate><title>Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine</title><author>Boushaki, F. Z. ; Rasio, E. ; Serri, O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4362-bf5c484dc9074f586e7addedf2b489b547a4278f3d9cf84a66783809061989f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adrenocorticotropic Hormone - blood</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Body Constitution</topic><topic>Body Mass Index</topic><topic>Corticotropin-Releasing Hormone</topic><topic>Cross-Over Studies</topic><topic>Female</topic><topic>Fenfluramine - therapeutic use</topic><topic>Humans</topic><topic>Hydrocortisone - blood</topic><topic>Hypothalamo-Hypophyseal System - drug effects</topic><topic>Hypothalamo-Hypophyseal System - physiopathology</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Naloxone</topic><topic>Narcotic Antagonists</topic><topic>Obesity</topic><topic>Obesity - blood</topic><topic>Obesity - drug therapy</topic><topic>Obesity - physiopathology</topic><topic>Pituitary-Adrenal System - drug effects</topic><topic>Pituitary-Adrenal System - physiopathology</topic><topic>Serotonin Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boushaki, F. Z.</creatorcontrib><creatorcontrib>Rasio, E.</creatorcontrib><creatorcontrib>Serri, O.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boushaki, F. Z.</au><au>Rasio, E.</au><au>Serri, O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clinical Endocrinology</addtitle><date>1997-04</date><risdate>1997</risdate><volume>46</volume><issue>4</issue><spage>461</spage><epage>466</epage><pages>461-466</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract>OBJECTIVE Hyperactivity of the HPA axis is a possible mechanism underlying abdominal obesity. We aimed to evaluate in premenopausal women with abdominal obesity, (i) the hypothalamic‐pituitary‐adrenal (HPA) axis responses to direct pituitary stimulation with corticotrophin releasing hormone (CRH) and to opioid blockade with naloxone, and (ii) the interaction between short‐term serotoninergic activation with dexfenfluramine (dF), a serotonin‐release agonist, and these responses.
DESIGN AND SUBJECTS Eight obese women (mean BMI, 35 kg/m2) with waist to hip ratio (WHR) > 0.85 were tested with CRH (1 μg/kg i.v.) and naloxone (125 μg/kg i.v.) before and at the end of two treatment periods with dF (15 mg twice daily for 7 days) and placebo (washout 7 days) in a cross‐over design. Eight normal weight control women were tested with CRH and naloxone.
RESULTS Prior to treatment, ACTH and cortisol responses to naloxone (areas under the curve) were significantly higher in obese women then in control women (P=0.027 and P=0.035 respectively). dF treatment resulted in significant (P<0.05) reduction of ACTH and cortisol increments. In contrast, ACTH and cortisol responses to CRH were not significantly different in obese and control subjects and were unaffected by dF treatment.
CONCLUSION We conclude that women with abdominal obesity have hyperreactivity of the HPA axis to opiod blockage and that dexfenfluramine treatment reduces this hyperreactivity.</abstract><cop>Oxford BSL</cop><pub>Blackwell Science Ltd</pub><pmid>9196609</pmid><doi>10.1046/j.1365-2265.1997.1620975.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 1997-04, Vol.46 (4), p.461-466 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79069612 |
| source | MEDLINE; Wiley Journals |
| subjects | Adrenocorticotropic Hormone - blood Adult Biological and medical sciences Body Constitution Body Mass Index Corticotropin-Releasing Hormone Cross-Over Studies Female Fenfluramine - therapeutic use Humans Hydrocortisone - blood Hypothalamo-Hypophyseal System - drug effects Hypothalamo-Hypophyseal System - physiopathology Medical sciences Metabolic diseases Naloxone Narcotic Antagonists Obesity Obesity - blood Obesity - drug therapy Obesity - physiopathology Pituitary-Adrenal System - drug effects Pituitary-Adrenal System - physiopathology Serotonin Agents - therapeutic use |
| title | Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A57%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypothalamic-pituitary-adrenal%20axis%20in%20abdominal%20obesity:%20effects%20of%20dexfenfluramine&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Boushaki,%20F.%20Z.&rft.date=1997-04&rft.volume=46&rft.issue=4&rft.spage=461&rft.epage=466&rft.pages=461-466&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1046/j.1365-2265.1997.1620975.x&rft_dat=%3Cproquest_cross%3E79069612%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79069612&rft_id=info:pmid/9196609&rfr_iscdi=true |